Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Eli Lilly

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

The Guardian - UK

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

Fortune

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

Zenger

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

StockNews.com

Weight loss jab rejected for NHS use over effectiveness concerns - despite positive trials

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

Nottingham Post

Weight loss injection rejected for NHS use over effectiveness concerns

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

Wales Online

Weight-loss jab rejected for NHS use by England drugs watchdog

Nice says more evidence needed on effectiveness of tirzepatide, sold under brand name Mounjaro

The Guardian - UK

More info needed on weight-loss jab’s impact on type 2 diabetes – Nice

The once-weekly jab would be offered to diabetic patients alongside diet and exercise,

The Independent UK

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

How companies can strengthen their workforces in an uncertain labor market

While tech layoffs make splashy headlines, other industries like health care, financial services, and education are eager to scoop up tech workers.

Barchart

Chart of the Day: Eli Lilly - A Retail Investor Favorite

The Chart of the Day belongs to the pharmaceutical company Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Barchart

Stocks Fall on Chinese Economic Concerns and Wariness Ahead of Fed Chair Powell

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.77%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.73%. U.S. stocks this morning are moderately lower. U.S. stocks...

Barchart

Markets Today: Stocks Slip on China Economic Concerns and Higher Bond Yields

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.33%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.28%. U.S. stock index futures this morning are moderately lower. Negative carry-over from a decline in Chinese stocks is weighing on U.S. stock index futures on...

Get all your
news in one place.

100's of premium titles.
One news app.

Chicago Tribune

Commentary: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

Daily Record

New weekly obesity injection could help people rapidly shed body weight

The National Institute for Health and Care Excellence (Nice) is judging whether or not the jab would be a good use of NHS funds.

Wales Online

New once-a week injection helps people lose large amount of weight

The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds

The Independent UK

New obesity jab that sparked diabetes row in US could get NHS green light

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

The Conversation

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The New Daily

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

The New Daily

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

1 … 23 24 25 26

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Warner Bros Discovery

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.